Business
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process SOUTH SAN
About this update from Quince Therapeutics, Inc.
[{"type":"text","content":"\nAllowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771 entitled Process for the Preparation of Erythrocytes Loaded With One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes. The newly allowed application covers the method of treating patients with Ataxia-Telangiectasia (A-T) and provides patent coverage for preparing erythrocytes loaded with one or more substances of pharmaceutical interest using the EryDex process. The first independent claim of this application is not limited to any particular pharmaceutical product and is broader than currently granted parent patent claims. Supplementing the company’s existing U.S. Patent No. 10,849,858, Quince now has issued patents directed to the process for encapsulating erythrocytes with a therapeutic drug as well as a method of treating a patient with encapsulated erythrocytes.\n\n\nCharles Ryan, J.D., Ph.D., Quince’s President and head of the company’s corporate legal activities and intellectual property portfolio, said, “Our growing intellectual property portfolio strengthens the long-term market position for our lead asset EryDex and further validates our proprietary AIDE technology platform. Importantly, this allowance strengthens market exclusivity and extends our patent claims to 2036 in the U.S. We are very pleased with this Notice of Allowance and intend to continue to prosecute additional patent applications to protect EryDex and our proprietary encapsulation technology.”\n\n\nQuince expects that the resulting patent will be listable in the U.S. Food and Drug Administration’s publication Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). As a result, any generic applicant that references EryDex for the treatment of A-T would be required to certify against the company’s patent. This will provide Quince notice of future generic applicants and give the company other stay provisions under...